Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/CDK13_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/CDK13_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/CDK13_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/CDK13_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/CDK13_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CDK13_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/CDK13_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/CDK13_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/CDK13_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/CDK13_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:20007375 | Esophagus | HGIN | negative regulation of stem cell differentiation | 12/2587 | 23/18723 | 1.45e-05 | 4.02e-04 | 12 |
GO:20007365 | Esophagus | HGIN | regulation of stem cell differentiation | 20/2587 | 58/18723 | 5.65e-05 | 1.33e-03 | 20 |
GO:00063548 | Esophagus | HGIN | DNA-templated transcription, elongation | 27/2587 | 91/18723 | 6.62e-05 | 1.52e-03 | 27 |
GO:00342435 | Esophagus | HGIN | regulation of transcription elongation from RNA polymerase II promoter | 13/2587 | 32/18723 | 1.72e-04 | 3.32e-03 | 13 |
GO:01400146 | Esophagus | HGIN | mitotic nuclear division | 61/2587 | 287/18723 | 3.38e-04 | 5.55e-03 | 61 |
GO:00327866 | Esophagus | HGIN | positive regulation of DNA-templated transcription, elongation | 11/2587 | 27/18723 | 5.28e-04 | 7.56e-03 | 11 |
GO:00329685 | Esophagus | HGIN | positive regulation of transcription elongation from RNA polymerase II promoter | 7/2587 | 13/18723 | 7.61e-04 | 1.00e-02 | 7 |
GO:00327844 | Esophagus | HGIN | regulation of DNA-templated transcription, elongation | 16/2587 | 53/18723 | 1.58e-03 | 1.79e-02 | 16 |
GO:00708162 | Esophagus | HGIN | phosphorylation of RNA polymerase II C-terminal domain | 6/2587 | 12/18723 | 3.03e-03 | 2.88e-02 | 6 |
GO:0008380111 | Esophagus | ESCC | RNA splicing | 336/8552 | 434/18723 | 1.74e-42 | 3.67e-39 | 336 |
GO:0000375111 | Esophagus | ESCC | RNA splicing, via transesterification reactions | 248/8552 | 324/18723 | 3.05e-30 | 1.49e-27 | 248 |
GO:0000377111 | Esophagus | ESCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 244/8552 | 320/18723 | 2.52e-29 | 1.07e-26 | 244 |
GO:0000398111 | Esophagus | ESCC | mRNA splicing, via spliceosome | 244/8552 | 320/18723 | 2.52e-29 | 1.07e-26 | 244 |
GO:014001414 | Esophagus | ESCC | mitotic nuclear division | 218/8552 | 287/18723 | 6.17e-26 | 1.78e-23 | 218 |
GO:000734615 | Esophagus | ESCC | regulation of mitotic cell cycle | 293/8552 | 457/18723 | 8.00e-16 | 5.64e-14 | 293 |
GO:000635414 | Esophagus | ESCC | DNA-templated transcription, elongation | 76/8552 | 91/18723 | 8.35e-14 | 4.11e-12 | 76 |
GO:00482853 | Esophagus | ESCC | organelle fission | 301/8552 | 488/18723 | 4.64e-13 | 2.12e-11 | 301 |
GO:00002802 | Esophagus | ESCC | nuclear division | 270/8552 | 439/18723 | 1.17e-11 | 4.24e-10 | 270 |
GO:000636814 | Esophagus | ESCC | transcription elongation from RNA polymerase II promoter | 56/8552 | 69/18723 | 1.40e-09 | 3.30e-08 | 56 |
GO:003278412 | Esophagus | ESCC | regulation of DNA-templated transcription, elongation | 45/8552 | 53/18723 | 3.64e-09 | 7.61e-08 | 45 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CDK13 | SNV | Missense_Mutation | | c.1738N>G | p.Leu580Val | p.L580V | Q14004 | protein_coding | tolerated(0.95) | benign(0) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
CDK13 | SNV | Missense_Mutation | | c.2522N>T | p.Ser841Phe | p.S841F | Q14004 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
CDK13 | SNV | Missense_Mutation | | c.2045N>A | p.Ile682Lys | p.I682K | Q14004 | protein_coding | deleterious(0.01) | probably_damaging(0.96) | TCGA-AN-A0FW-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
CDK13 | SNV | Missense_Mutation | | c.2866N>C | p.Tyr956His | p.Y956H | Q14004 | protein_coding | tolerated(0.1) | possibly_damaging(0.673) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CDK13 | SNV | Missense_Mutation | | c.1865N>T | p.Ala622Val | p.A622V | Q14004 | protein_coding | tolerated(0.42) | benign(0.025) | TCGA-D8-A1XC-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
CDK13 | SNV | Missense_Mutation | novel | c.3716N>G | p.Asp1239Gly | p.D1239G | Q14004 | protein_coding | deleterious_low_confidence(0.02) | benign(0.154) | TCGA-GM-A3XL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | CR |
CDK13 | SNV | Missense_Mutation | novel | c.3806C>T | p.Pro1269Leu | p.P1269L | Q14004 | protein_coding | deleterious_low_confidence(0.04) | probably_damaging(0.923) | TCGA-LD-A74U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | taxotere | SD |
CDK13 | SNV | Missense_Mutation | novel | c.2159N>G | p.Tyr720Cys | p.Y720C | Q14004 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-LL-A73Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD |
CDK13 | insertion | In_Frame_Ins | novel | c.1809_1810insGTCTGGAAA | p.Val603_Thr604insValTrpLys | p.V603_T604insVWK | Q14004 | protein_coding | | | TCGA-A7-A0CJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
CDK13 | insertion | Frame_Shift_Ins | novel | c.3817_3818insTAAATGTCTCCAT | p.Glu1273ValfsTer25 | p.E1273Vfs*25 | Q14004 | protein_coding | | | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
8621 | CDK13 | ENZYME, KINASE, DRUGGABLE GENOME, SERINE THREONINE KINASE | inhibitor | 375973251 | | |
8621 | CDK13 | ENZYME, KINASE, DRUGGABLE GENOME, SERINE THREONINE KINASE | inhibitor | CHEMBL3544942 | RONICICLIB | |
8621 | CDK13 | ENZYME, KINASE, DRUGGABLE GENOME, SERINE THREONINE KINASE | inhibitor | CHEMBL488436 | AZD-5438 | |
8621 | CDK13 | ENZYME, KINASE, DRUGGABLE GENOME, SERINE THREONINE KINASE | inhibitor | CHEMBL445813 | AT-7519 | |
8621 | CDK13 | ENZYME, KINASE, DRUGGABLE GENOME, SERINE THREONINE KINASE | inhibitor | CHEMBL1230607 | PHA-793887 | |